Literature DB >> 25859248

Apoptotic cell clearance and its role in the origin and resolution of chronic inflammation.

Luis Enrique Muñoz1, Christian Berens2, Kirsten Lauber3, Udo S Gaipl4, Martin Herrmann1.   

Abstract

Entities:  

Keywords:  atherosclerosis; autoimmunity; cancer; cell death; chronic; clearance; inflammation; phagocytosis

Year:  2015        PMID: 25859248      PMCID: PMC4373391          DOI: 10.3389/fimmu.2015.00139

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


× No keyword cloud information.
During normal tissue turnover, innate immune sentinels swiftly clear dying cells in an immunologically silent manner. Large amounts of nuclear chromatin are meticulously kept away from the immune system to prevent inflammation and, eventually, autoimmunity from developing. In case this highly efficient surveillance system is derailed, the unanticipated presence of post-mortem remnants in tissues can challenge the otherwise normally ensuing immunological tolerance. Apoptotic cell death is the most natural way to preserve this precious tissue homeostasis. Early recognition and swift clearance of cells undergoing apoptosis ensures the prevention of tissue damage and autoimmune reactions (1). Kimani et al. thoroughly review in this Research Topic, the most recent evidence linking autoimmune diseases and the recognition of apoptotic cells via surface-exposed phosphatidylserine (2). Besides the autoimmune phenotype of chronic inflammatory rheumatoid disorders, a plethora of pathologies have been associated with defects in genes involved in the clearance of cell remnants from tissues (3, 4). This Research Topic bundles a set of manuscripts describing various ways of how such “uncleared” cell remnants participate in the pathogenesis of chronic inflammatory diseases and also cancer. Improving our knowledge of the immune modulatory language(s) spoken by dying and dead cells and their constituents may prove essential for understanding the key processes involved. Ultimately and hopefully, this may lead to the development of new classes of therapeutic and disease-modifying agents (5). For example, González and Hidalgo emphasize that it is now possible to take advantage of the huge amount of published evidence on therapeutic modulation of the liver X receptor activity in clearance-associated diseases (6). Notably, pharmacological regulation of such nuclear factors, which are activated upon recognition of dying cells, may enhance the ability of macrophages to clear dead cells and thereby provide additional beneficial effects for treating clearance-related diseases like osteoporosis, rheumatoid arthritis, atherosclerosis, diabetes, and Alzheimer’s disease (7–10). Upon recruitment to sites of acute inflammation, neutrophils respond either with phagocytosis of the inflammatory trigger, degranulation, or with the formation of neutrophil-extracellular-traps (NETs) (11) exposing modified chromatin at the site of the initial injury (12). The nature of this material implies the massive death of neutrophils, and this response is important for both the inactivation of the aggressor and the resolution of the initial inflammation (13). However, how this battlefield is finally cleaned up and cleared has not been studied yet and may surely provide new therapeutic options for autoimmune diseases (12, 14). Intense current research on the immunobiology of this special way of dying called NETosis also promises new therapeutic targets for ameliorating autoinflammation (15, 16). Severe and standard treatment resistant forms of pulmonary inflammation may also profit by novel dual interventions targeting both cell survival and promotion of apoptotic cell clearance by phagocytes as Felton et al. and Szondy et al. summarize in this issue (17, 18). Although one of the multiple mechanisms of action of glucocorticoids is to enhance apoptotic cell clearance by macrophages (19), their long-term use has many side effects that strongly burden chronically diseased patients leading to higher rates of morbidity. Alternatives to classic therapies and specific pathogenesis-targeted therapies are therefore very much welcome. The many different signals expressed or secreted by apoptotic cells noticeably determine the reaction of the organism to the event triggering death. Any shortcomings in phagocytic clearance, either by impaired clearance, excessive death or any other reason, are invariably related to continuous stimulation of the organism by either pro-inflammatory/destructive or anti-inflammatory/healing signaling. Many chronic inflammatory diseases are driven and somehow modulated by metabolites released from dying cells. For example, Chen et al. present an overview of the various sites of action of nucleotides in inflammatory conditions (20). Intervention at this level may shift the balance toward anti-inflammation, thereby achieving the therapeutic goal more effectively. In the case of solid tumors, the metabolites and, especially, the danger signals released may serve as biomarkers. Gehrmann et al. nicely demonstrate in this Research Topic that stress response proteins are released already by premalignant conditions of the liver as well as by hepatocellular carcinoma (21). This can be important for prognosis, prediction, and monitoring. The tumor microenvironment, especially directly after anti-cancer treatment, is overflowing with mediators and signals from dead and dying cells. To obtain an efficient anti-tumor immune response, an immune-suppressive microenvironment has to be shifted to an activating one. The latter might be achieved by rendering the tumor cells immunogenic, namely, by inducing immunogenic tumor cell death forms by standard treatments such as radio- and/or chemotherapy (22). Furthermore, short range danger signals foster leukocyte infiltration into the tumor and initiate an inflammatory response, which is afterwards supplanted by long-range healing and regenerative signals, which then, in contrast, may support tumor proliferation. The review from Willems summarizes evidence documenting the dark side of apoptosis in modulating anti-tumor responses (23). A delicate balance exists between anti-tumor reactions and counteracting immune suppression. In this scenario, the role of tumor associated macrophages as sensors and central orchestrators of tumor-promoting reparatory and anti-inflammatory signals has recently been highlighted by Ford et al. (24). In addition, avoiding tumor repopulation after anti-cancer therapy by considering the immune-suppressive consequences of apoptotic cell clearance should be taken into account as a cautionary premise for each and every anti-cancer treatment (25–28). Of note, inflammatory reactions, DNA damage responses, and cell death forms are highly interconnected (29). Alterations in the clearance of dying and dead cells, their remnants, and their constituents that leak out after membrane rupture are therefore central elements in all inflammatory conditions, starting from its origin and ending in its resolution.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  29 in total

1.  Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss.

Authors:  Arnd Kleyer; Carina Scholtysek; Edith Bottesch; Ulrike Hillienhof; Christian Beyer; Jörg Hw Distler; Jan P Tuckermann; Georg Schett; Gerhard Krönke
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

Review 2.  The role of defective clearance of apoptotic cells in systemic autoimmunity.

Authors:  Luis E Muñoz; Kirsten Lauber; Martin Schiller; Angelo A Manfredi; Martin Herrmann
Journal:  Nat Rev Rheumatol       Date:  2010-05       Impact factor: 20.543

Review 3.  Antitumor immune responses induced by ionizing irradiation and further immune stimulation.

Authors:  Benjamin Frey; Yvonne Rubner; Lorenz Kulzer; Nina Werthmöller; Eva-Maria Weiss; Rainer Fietkau; Udo S Gaipl
Journal:  Cancer Immunol Immunother       Date:  2013-09-20       Impact factor: 6.968

4.  Milk fat globule-EGF factor 8 mediates the enhancement of apoptotic cell clearance by glucocorticoids.

Authors:  K Lauber; H Keppeler; L E Munoz; U Koppe; K Schröder; H Yamaguchi; G Krönke; S Uderhardt; S Wesselborg; C Belka; S Nagata; M Herrmann
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

Review 5.  Apoptotic cell clearance: basic biology and therapeutic potential.

Authors:  Ivan K H Poon; Christopher D Lucas; Adriano G Rossi; Kodi S Ravichandran
Journal:  Nat Rev Immunol       Date:  2014-01-31       Impact factor: 53.106

6.  The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.

Authors:  Radosveta P Koldamova; Iliya M Lefterov; Matthias Staufenbiel; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; Michael Walter; Michael G Roth; John S Lazo
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

7.  Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy.

Authors:  Qian Huang; Fang Li; Xinjian Liu; Wenrong Li; Wei Shi; Fei-Fei Liu; Brian O'Sullivan; Zhimin He; Yuanlin Peng; Aik-Choon Tan; Ling Zhou; Jingping Shen; Gangwen Han; Xiao-Jing Wang; Jackie Thorburn; Andrew Thorburn; Antonio Jimeno; David Raben; Joel S Bedford; Chuan-Yuan Li
Journal:  Nat Med       Date:  2011-07-03       Impact factor: 53.440

8.  Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapy.

Authors:  Kirsten Lauber; Luis E Munoz; Christian Berens; Verena Jendrossek; Claus Belka; Martin Herrmann
Journal:  Radiat Oncol       Date:  2011-12-19       Impact factor: 3.481

Review 9.  Clearance of Apoptotic Bodies, NETs, and Biofilm DNA: Implications for Autoimmunity.

Authors:  Marko Radic
Journal:  Front Immunol       Date:  2014-07-30       Impact factor: 7.561

10.  Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis.

Authors:  Darren L Asquith; Ashley M Miller; Axel J Hueber; Heather J McKinnon; Naveed Sattar; Gerry J Graham; Iain B McInnes
Journal:  Arthritis Rheum       Date:  2009-09
View more
  6 in total

1.  CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages.

Authors:  Patrick S Murphy; Jing Wang; Samir P Bhagwat; Joshua C Munger; William J Janssen; Terry W Wright; Michael R Elliott
Journal:  Cell Death Differ       Date:  2017-01-06       Impact factor: 15.828

Review 2.  The Dynamics of Apoptotic Cell Clearance.

Authors:  Michael R Elliott; Kodi S Ravichandran
Journal:  Dev Cell       Date:  2016-07-25       Impact factor: 12.270

3.  Immune correlates of tuberculosis disease and risk translate across species.

Authors:  Mushtaq Ahmed; Shyamala Thirunavukkarasu; Bruce A Rosa; Kimberly A Thomas; Shibali Das; Javier Rangel-Moreno; Lan Lu; Smriti Mehra; Stanley Kimbung Mbandi; Larissa B Thackray; Michael S Diamond; Kenneth M Murphy; Terry Means; John Martin; Deepak Kaushal; Thomas J Scriba; Makedonka Mitreva; Shabaana A Khader
Journal:  Sci Transl Med       Date:  2020-01-29       Impact factor: 19.319

Review 4.  Clearance of Apoptotic Cells by Tissue Epithelia: A Putative Role for Hepatocytes in Liver Efferocytosis.

Authors:  Scott P Davies; Gary M Reynolds; Zania Stamataki
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

5.  Discovering Molecules That Regulate Efferocytosis Using Primary Human Macrophages and High Content Imaging.

Authors:  Sandra Santulli-Marotto; Alexis Gervais; Jamie Fisher; Brandy Strake; Carol Anne Ogden; Chelsea Riveley; Jill Giles-Komar
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

6.  Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro.

Authors:  Gerhard E Grossmayer; Hildegard Keppeler; Sebastian Boeltz; Christina Janko; Jürgen Rech; Martin Herrmann; Kirsten Lauber; Luis E Muñoz
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.